169 related articles for article (PubMed ID: 18337021)
1. Differential efficacy of combined therapy with radiation and AEE788 in high and low EGFR-expressing androgen-independent prostate tumor models.
Huamani J; Willey C; Thotala D; Niermann KJ; Reyzer M; Leavitt L; Jones C; Fleishcher A; Caprioli R; Hallahan DE; Kim DW
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):237-46. PubMed ID: 18337021
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.
Sasaki T; Kitadai Y; Nakamura T; Kim JS; Tsan RZ; Kuwai T; Langley RR; Fan D; Kim SJ; Fidler IJ
Neoplasia; 2007 Dec; 9(12):1066-77. PubMed ID: 18084614
[TBL] [Abstract][Full Text] [Related]
3. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
4. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
Younes MN; Park YW; Yazici YD; Gu M; Santillan AA; Nong X; Kim S; Jasser SA; El-Naggar AK; Myers JN
Mol Cancer Ther; 2006 Nov; 5(11):2696-705. PubMed ID: 17121916
[TBL] [Abstract][Full Text] [Related]
5. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ
Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138
[TBL] [Abstract][Full Text] [Related]
7. Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells.
Busby JE; Kim SJ; Yazici S; Nakamura T; Kim JS; He J; Maya M; Wang X; Do KA; Fan D; Fidler IJ
Prostate; 2006 Dec; 66(16):1788-98. PubMed ID: 17013882
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models.
Oehler-Jänne C; Jochum W; Riesterer O; Broggini-Tenzer A; Caravatti G; Vuong V; Pruschy M
Mol Cancer Ther; 2007 Sep; 6(9):2496-504. PubMed ID: 17876047
[TBL] [Abstract][Full Text] [Related]
9. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice.
Park YW; Younes MN; Jasser SA; Yigitbasi OG; Zhou G; Bucana CD; Bekele BN; Myers JN
Clin Cancer Res; 2005 Mar; 11(5):1963-73. PubMed ID: 15756022
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
Yokoi K; Thaker PH; Yazici S; Rebhun RR; Nam DH; He J; Kim SJ; Abbruzzese JL; Hamilton SR; Fidler IJ
Cancer Res; 2005 May; 65(9):3716-25. PubMed ID: 15867367
[TBL] [Abstract][Full Text] [Related]
11. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade.
Yigitbasi OG; Younes MN; Doan D; Jasser SA; Schiff BA; Bucana CD; Bekele BN; Fidler IJ; Myers JN
Cancer Res; 2004 Nov; 64(21):7977-84. PubMed ID: 15520205
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ
Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027
[TBL] [Abstract][Full Text] [Related]
13. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788.
Kim S; Schiff BA; Yigitbasi OG; Doan D; Jasser SA; Bekele BN; Mandal M; Myers JN
Mol Cancer Ther; 2005 Apr; 4(4):632-40. PubMed ID: 15827337
[TBL] [Abstract][Full Text] [Related]
14. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
Younes MN; Yigitbasi OG; Park YW; Kim SJ; Jasser SA; Hawthorne VS; Yazici YD; Mandal M; Bekele BN; Bucana CD; Fidler IJ; Myers JN
Cancer Res; 2005 Jun; 65(11):4716-27. PubMed ID: 15930290
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
Goudar RK; Shi Q; Hjelmeland MD; Keir ST; McLendon RE; Wikstrand CJ; Reese ED; Conrad CA; Traxler P; Lane HA; Reardon DA; Cavenee WK; Wang XF; Bigner DD; Friedman HS; Rich JN
Mol Cancer Ther; 2005 Jan; 4(1):101-12. PubMed ID: 15657358
[TBL] [Abstract][Full Text] [Related]
16. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
17. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
18. Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy.
Kuwai T; Nakamura T; Sasaki T; Kitadai Y; Kim JS; Langley RR; Fan D; Wang X; Do KA; Kim SJ; Fidler IJ
Clin Exp Metastasis; 2008; 25(4):477-89. PubMed ID: 18324358
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice.
Yokoi K; Kim SJ; Thaker P; Yazici S; Nam DH; He J; Sasaki T; Chiao PJ; Sclabas GM; Abbruzzese JL; Hamilton SR; Fidler IJ
Neoplasia; 2005 Jul; 7(7):696-704. PubMed ID: 16026649
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
Wachsberger PR; Lawrence YR; Liu Y; Daroczi B; Xu X; Dicker AP
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):483-91. PubMed ID: 21095630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
